Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
J Thorac Oncol
; 3(6 Suppl 2): S128-30, 2008 Jun.
Article
em En
| MEDLINE
| ID: mdl-18520295
ABSTRACT
Vandetinib is a novel, selective dual inhibitor of the vascular endothelial growth factor receptor pathway and epidermal growth factor receptor pathway. Phase I studies have established that it is suitable for once-daily oral dosing at a dose of up to 300 mg. Vandetinib has been tested in multiple randomized controlled phase II clinical studies, which have established that this is a promising new targeted agent for the treatment of patients with advanced non-small cell lung cancer and which also support the potential role of vandetinib administered concurrently with chemotherapy. Further testing of its role in lung cancer is in ongoing.
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
2_ODS3
/
6_ODS3_enfermedades_notrasmisibles
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Quinazolinas
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores da Angiogênese
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Receptores ErbB
/
Neoplasias Pulmonares
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Thorac Oncol
Ano de publicação:
2008
Tipo de documento:
Article